Skip to main content
. 2017 Jul 7;8(65):108430–108450. doi: 10.18632/oncotarget.19086

Figure 5. GW6471 effects on glycogen storage and metabolism of GSCs.

Figure 5

A. Glycogen levels in treated GSCs by confocal microscopy shows that glycogen is highly present in hypoxic neurospheres and that GW6471 is able to decrease glycogen both in normoxic and hypoxic neurospheres. Nuclei are stained with Dapi. Bar = 25µm. B. Western blotting analysis for GPBB, GSK3β, p-GS3Kβ-ser9, Hexokinase and PKM2. Data are means ± SD of 3 different experiments. +, p < 0.01, ++, p < 0.001, +++, p < 0.0001, hypoxia with respect to the respective control; °, p < 0.01, °°, p < 0.001, hypoxia vs normoxia. **, p < 0.001, normoxia vs the respective control. C. GLUT-3 immunofluorescence in treated GSCs in normoxic and hypoxic conditions shows that GLUT-3 is increased in hypoxia and that the treatment decreases the transporter both in normoxia and hypoxia. Nuclei are stained with Dapi. Bar = 25µm. D. Glucose uptake in treated GSCs by deoxy-glucose analog shows that the treatment was able to decrease glucose uptake. Nuclei are stained with Dapi Bar = 25µm.